Inotiv, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert W. Leasure Jr.
- Full Time Employees
- 1,945
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2701 Kent Avenue West Lafayette IN United States of America 47906
- IPO Date
- Nov 25, 1997
- CIK
- 0000720154
- Website
- inotiv.com
- Similar Companies
- Business
- Inotiv, Inc. is a contract research organization that provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries, with operations across the United States, the Netherlands, and international markets. It is organized around two primary business segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS), complemented by the BASi line of scientific instruments and related software under the DMS umbrella. Main products and services: - Nonclinical pharmacology, toxicology, and safety assessment services: computational toxicology, disease pharmacology, DMPK, safety pharmacology, general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, reproductive toxicology, and development toxicity testing. - Bioanalytical services: discovery bioanalysis, nonregulated discovery bioanalysis, regulated preclinical and clinical bioanalysis, biotherapeutics analysis, and associated assay development and validation. - Pathology and histology: histology, digital pathology, clinical pathology, medical device pathology, and related reporting. - Proteomics and molecular biology: proteomics services and cell/molecular biology capabilities to support drug discovery and development. - Research model development and services: supply of research models, animal models, laboratory diets, bedding, and related bioproducts through the RMS unit. - Instrumentation and software: BASi product line covering scientific instruments for life sciences research and associated software for pharmaceutical companies, universities, and research institutions. - Consulting and related scientific services: project management, study design support, and regulatory guidance as part of discovery and preclinical programs. Geographic operations and markets: - Primary focus in North America and Europe, with clients including pharmaceutical companies, biotechnology firms, universities, government research centers, and medical research institutions. - Global facilities and capabilities enable cross-border studies and international collaborations. Founding year and headquarters: - Founded in 2004 and headquartered in Lafayette, Indiana, United States, with growth through expansion of facilities and capability enhancements in recent years. Latest major company changes: - Transformational expansion and operational consolidation projects completed or near completion in the last 1–2 years, including major facility upgrades and capacity expansions to support additional long-term contracts and new customers, and the planned consolidation of associated sites under centralized operations to improve efficiency and safety; these changes reflect strategic shifts toward improving infrastructure, animal welfare, and safety standards while enabling scale to support growth. - Ongoing portfolio enhancements and site improvements to support growth in discovery services, safety assessment, and research models, reflecting a broader strategy to broaden service offerings and geographic reach. Subsidiaries and corporate relationships: - Operates through its two principal business units: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS); maintains BASi instrumentation and software offerings as part of its product and service ecosystem. - Inotiv’s strategy emphasizes integration across nonclinical discovery, analytical testing, and research models, aligning client needs with end-to-end preclinical and translational capabilities. Industry and segments: - Industry: Contract research organization (CRO) and life sciences research services. - Segments: Discovery and Safety Assessment (DSA); Research Models and Services (RMS); BASi instrumentation and software for life-sciences research. Target markets: - Biopharma companies, medical device developers, contract research customers, and academic/research institutions requiring nonclinical testing, analytical services, and research models. Notes: - Inotiv trades under ticker NOTVQ and has pursued a transformation plan since 2022 to optimize facilities, performance, and service delivery; the Hillcrest, U.K. expansion and related site consolidations represent significant recent operational milestones within the company’s global footprint.
Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth
Inotiv Provides Notice Regarding Cybersecurity Incident
Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript
Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026
Ernexa Therapeutics (NASDAQ:ERNA) vs. Inotiv (NASDAQ:NOTV) Critical Review
Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities
Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™
Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025
Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results
Halper Sadeh LLC Encourages Inotiv, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Inotiv, Inc. to Participate in Three Investor Conferences in September 2025
Inotiv, Inc. (NOTV) Q3 2025 Earnings Call Transcript
CORRECTING and REPLACING - Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update
Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates
Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update
Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025